A peptide gel for early cavities is now in 20,000 US dental offices

Curodont is a peptide treatment that dentists brush onto an early cavity, the chalky white spot that comes before a hole. It takes a few minutes, with no drilling and no needles. Its maker, vVardis, says it has now been sold to more than 20,000 of the roughly 110,000 general dental practices in the US, and in October 2026 the company filed to list on the New York Stock Exchange.

How it works

The active ingredient is a short lab-made peptide called P11-4. As its developers describe it, once applied to an early cavity it seeps into the weakened enamel and links up into a fine scaffold. Calcium and phosphate from saliva then build new mineral along that scaffold, rebuilding the enamel from the inside. Think of it as rebar for the tooth to pour new enamel onto.

What the trials found

A 2023 review in the Journal of the American Dental Association pooled the randomized trials. Early cavities treated with P11-4 were far more likely to stop progressing than untreated ones: about 73 in 100 lesions were arrested, against about 40 in 100 without it, and treated spots shrank by roughly a third on photographs Studied in humans. The effect was strongest when fluoride varnish was applied at the same visit.

The reviewers rated that evidence as moderate and asked for larger and longer trials. The studies followed patients for 6 to 12 months, and the manufacturer sponsored some of them.

Who it is for

Early cavities only. Once decay has broken through to form a hole, a filling is still the standard repair. In the US the product is sold as Curodont Repair Fluoride Plus, through dental offices, under the FDA’s rules for anticavity products.

Why it matters for peptides

It is one of the clearest examples of a peptide doing a precise physical job in the body: not a hormone signal, but a scaffold.